RISKYCAD
Personalized diagnostics and treatment of high risk coronary artery disease patients
| Coordinatore | "BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"
Organization address
address: Soranou Efesiou 4 contact info |
| Nazionalità Coordinatore | Greece [EL] |
| Totale costo | 7˙901˙915 € |
| EC contributo | 5˙992˙101 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2017-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"
Organization address
address: Soranou Efesiou 4 contact info |
EL (ATHENS) | coordinator | 1˙135˙720.00 |
| 2 |
COMPREHENSIVE BIOMARKER CENTER GMBH
Organization address
address: IM NEUENHEIMER FELD 519 contact info |
DE (HEIDELBERG) | participant | 671˙000.00 |
| 3 |
ZORA BIOSCIENCES LTD
Organization address
address: Biologinkuja 1 contact info |
FI (ESPOO) | participant | 641˙898.00 |
| 4 |
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Organization address
address: SEMINARSTRASSE 2 contact info |
DE (HEIDELBERG) | participant | 640˙400.00 |
| 5 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 581˙000.00 |
| 6 |
TAMPEREEN YLIOPISTO
Organization address
address: Kalevantie 4 contact info |
FI (TAMPERE) | participant | 545˙000.00 |
| 7 |
A. PERSIDIS & SIA OE
Organization address
address: RODOPOLEOS STREET 34 contact info |
EL (Athens) | participant | 497˙000.00 |
| 8 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | participant | 444˙000.00 |
| 9 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 399˙463.00 |
| 10 |
GENOWAY S.A.
Organization address
address: Avenue Jean Jaures 181 contact info |
FR (LYON) | participant | 364˙620.00 |
| 11 |
SYNLAB HOLDING GMBH
Organization address
address: GUBENER STRASSE 39 contact info |
DE (AUGSBURG) | participant | 72˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Although the accurate diagnosis and prevention of coronary artery disease (CAD), acute myocardial infarction (AMI) and death is a major public health issue, risk stratification for CAD with current diagnostic tools is not properly supporting clinical decision making. RiskyCAD’s overall goal is to identify novel biomarkers for asymptomatic patients in high risk of major coronary events, and develop new diagnostic tools and ‘personalized’ therapeutic strategies for this selected group of patients.
Taking advantage of the latest technologies, we will look into new biomarkers for asymptomatic patients in high risk of CAD using some of the finest cohorts (WP1), identify new molecules and develop new diagnostic kits that will be further validated in additional cohorts (WP6). We will generate reprogrammed iPS cell based human models for the study of metabolic aberrations in selected individual vulnerable CAD patients (WP2). We will identify defects, e.g. in liver lipid metabolism, in high risk CAD patients (WP3) and test targeted treatments in traditional and new preclinical animal models to provide proof-of-concept level evidence (WP4, WP5). As our approach is based on well characterized patients and phenotypes, we will generate clinically applicable stratification methods that will allow targeted treatment and patient enrichment for clinical trials (WP1). Unique predictive modelling and link identification platforms including Drug Repositioning will be used to select drugs or drug combinations that will best match the patient’s biomarker profile (WP7).
The final (translational) outcomes of this project will be: (i) a set of distinct biomarker test(s) for asymptomatic patients in high risk of CAD that can be ordered both by primary care physicians and specialized cardiologists from routine clinical laboratories; (ii) new CAD risk estimation models; (iii) a set of repositioned drugs ready to be exploited further for the optimal treatment of patients in high risk of CA'
Introduzione (Teaser)
In the developed world, cardiovascular events such as coronary artery disease (CAD) and myocardial infarction (MI) are major causes of death. There is a need for accurate risk stratification and new diagnostic tools to personalise therapy.